What the FDA labels say about taking them together
Momelotinib and rosuvastatin
Momelotinib's FDA label of July 20, 2026 names rosuvastatin in its drug interactions section, and rosuvastatin's label names momelotinib too. The rosuvastatin label: “Mechanism and Clinical Effect (s): Momelotinib increased rosuvastatin exposure by 2.7-fold.”
Check it at the source: the momelotinib FDA label on DailyMed (effective July 20, 2026, GlaxoSmithKline LLC); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).
What does the momelotinib label say about rosuvastatin?
Momelotinib label, drug interactionsBreast Cancer Resistance Protein (BCRP) substrates: Reduce rosuvastatin (BCRP substrate) dosage.
Source: FDA drug label (Ojjaara), GlaxoSmithKline LLC, effective July 20, 2026 (SPL set 4a672fd1-eb7b-4aa9-9b23-845e4b5dc400), via openFDA; the full label on DailyMed
What does the rosuvastatin label say about momelotinib?
Rosuvastatin label, drug interactionsMechanism and Clinical Effect (s): Momelotinib increased rosuvastatin exposure by 2.7-fold.
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Momelotinib | Rosuvastatin | |
|---|---|---|
| Labeled for | n/a | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.0692 per tablet 40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once